Canaccord analyst John Newman lowered the firm’s price target on Allogene Therapeutics to $14 from $35 and keeps a Buy rating on the shares. The firm removed value for ALLO-715 in Multiple Myeloma, and ALLO-501 in late-line LBCL. They currently model value for ALLO-501 in 1L LBCL maintenance, and in late- line CLL. They do not include value for ALLO-316 in Renal Cell Carcinoma, or ALLO-329 in Autoimmune Disease, representing upside to the firm’s current price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update
- Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update
- JMP Securities healthcare analysts hold an analyst/industry conference call
- Biotech Alert: Searches spiking for these stocks today
- Allogene activates three cancer centers as first sites for Phase 2 ALPHA3 trial